Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CHD stock price vs BIO: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BIO's multiple
Needs BIO P/E.
Implied fair value · at CHD's multiple
Needs CHD P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
CHURCH & DWIGHT CO., INC. · implied price per share
Bear
$37.82
Base
$45.81
Bull
$56.21
BIO-RAD LABORATORIES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PROCTER & GAMBLE Co
CHD vs PG
COLGATE PALMOLIVE CO
CHD vs CL
KIMBERLY CLARK CORP
CHD vs KMB
ESTEE LAUDER COMPANIES INC
CHD vs EL
DANAHER CORP /DE/
CHD vs DHR
ILLUMINA, INC.
CHD vs ILMN
AGILENT TECHNOLOGIES, INC.
CHD vs A
BIO-TECHNE Corp
CHD vs TECH
BRUKER CORP
CHD vs BRKR
Azenta, Inc.
CHD vs AZTA
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CHD’s superior ROIC and operating margin deserve a persistent premium to BIO, then hold or accumulate on weakness because CHD’s quality metrics are strong and its price is still inside its historical band despite the discount implied by the relative model.
CHD trades at a materially higher valuation than BIO on most earnings and cash-flow proxies, with the largest gap on P/E and EV/EBITDA. The model’s implied price of $35.29 versus the current $98.81 suggests a steep downside, but that result appears driven by the relative multiple framework rather than CHD’s operating quality.
Supporting Metrics
